Posted by Michael Wonder on 22 Mar 2021
Oakrum Pharma and Aucta Pharma announce U.S. FDA approval of generic version of Jadenu Sprinkle (deferasirox granules)
22 March 2021 - Oakrum Pharma in collaboration with Aucta Pharmaceuticals announced today the U.S. approval of a generic version of Jadenu sprinkle (deferasirox granules) in 90 mg, 180 mg and 360 mg strengths.
Deferasirox granules had annual sales in the U.S. exceeding $31 million in the aggregate for the 12-month period ending January 2021 according to available data from IQVIA.
